249 related articles for article (PubMed ID: 28386072)
1. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Tan PK; Liu S; Gunic E; Miner JN
Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
[TBL] [Abstract][Full Text] [Related]
2. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
[TBL] [Abstract][Full Text] [Related]
3. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
[TBL] [Abstract][Full Text] [Related]
5. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
Hou Z; Ma A; Mao J; Song D; Zhao X
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
[TBL] [Abstract][Full Text] [Related]
6. Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.
Cai W; Wu J; Liu W; Xie Y; Liu Y; Zhang S; Xu W; Tang L; Wang J; Zhao G
Molecules; 2018 Jan; 23(2):. PubMed ID: 29382075
[TBL] [Abstract][Full Text] [Related]
7. [Molecular mechanism in biological transport in the kidney: Urate transporter URAT1].
Hosoyamada M; Shibasaki T; Ichida K
Nihon Rinsho; 2006 Feb; 64 Suppl 2():176-9. PubMed ID: 16523883
[No Abstract] [Full Text] [Related]
8. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.
Huang W; Jiao S; Chen S; Chen Y; Yang Z; Wang W; Cao Z; Li Z; Zhang L
Bioorg Med Chem; 2022 Dec; 75():117073. PubMed ID: 36347120
[TBL] [Abstract][Full Text] [Related]
10. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
Smith WB; Hall J; Berg JK; Kazimir M; Yamamoto A; Walker S; Lee CA; Shen Z; Wilson DM; Zhou D; Gillen M; Marbury TC
Clin Drug Investig; 2018 Aug; 38(8):703-713. PubMed ID: 29949102
[TBL] [Abstract][Full Text] [Related]
11. A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
Leander J; Sunnåker M; Rekić D; Aksenov S; Eriksson UG; Johansson S; Parkinson J
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):525-541. PubMed ID: 33728547
[TBL] [Abstract][Full Text] [Related]
12. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.
Zhao ZA; Jiang Y; Chen YY; Wu T; Lan QS; Li YM; Li L; Yang Y; Lin CT; Cao Y; Zhou PZ; Guo JY; Tian YX; Pang JX
Acta Pharmacol Sin; 2022 Jan; 43(1):121-132. PubMed ID: 33767379
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
[TBL] [Abstract][Full Text] [Related]
14. Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
Zhao T; Meng Q; Sun Z; Chen Y; Ai W; Zhao Z; Kang D; Dong Y; Liang R; Wu T; Pang J; Liu X; Zhan P
J Med Chem; 2020 Oct; 63(19):10829-10854. PubMed ID: 32897699
[TBL] [Abstract][Full Text] [Related]
15. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
[TBL] [Abstract][Full Text] [Related]
16. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.
Shin HJ; Takeda M; Enomoto A; Fujimura M; Miyazaki H; Anzai N; Endou H
Nephrology (Carlton); 2011 Feb; 16(2):156-62. PubMed ID: 21272127
[TBL] [Abstract][Full Text] [Related]
17. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Tan PK; Farrar JE; Gaucher EA; Miner JN
Mol Biol Evol; 2016 Sep; 33(9):2193-200. PubMed ID: 27352852
[TBL] [Abstract][Full Text] [Related]
18. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
Hamada T; Ichida K; Hosoyamada M; Mizuta E; Yanagihara K; Sonoyama K; Sugihara S; Igawa O; Hosoya T; Ohtahara A; Shigamasa C; Yamamoto Y; Ninomiya H; Hisatome I
Am J Hypertens; 2008 Oct; 21(10):1157-62. PubMed ID: 18670416
[TBL] [Abstract][Full Text] [Related]
19. URAT1 inhibition by ALPK1 is associated with uric acid homeostasis.
Kuo TM; Huang CM; Tu HP; Min-Shan Ko A; Wang SJ; Lee CP; Ko YC
Rheumatology (Oxford); 2017 Apr; 56(4):654-659. PubMed ID: 28039413
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout.
Wu JW; Yin L; Liu YQ; Zhang H; Xie YF; Wang RL; Zhao GL
Bioorg Med Chem Lett; 2019 Feb; 29(3):383-388. PubMed ID: 30579795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
